Koers e-therapeutics plc London S.E.
Aandelen
ETX
GB00B2823H99
Biotechnologie & Medisch Onderzoek
Omzet 2023 | 475K 600K 561K | Omzet 2024 | 318K 402K 376K | Marktkapitalisatie | 95,46 mln. 121 mln. 113 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 | -8 mln. -10,1 mln. -9,45 mln. | Nettowinst (verlies) 2024 | -11 mln. -13,89 mln. -12,99 mln. | EV/omzet 2023 | 186 x |
Nettoliquiditeiten 2023 | 31,39 mln. 39,65 mln. 37,08 mln. | Nettoliquiditeiten 2024 | 19,96 mln. 25,2 mln. 23,57 mln. | EV/omzet 2024 | 237 x |
K/w-verhouding 2023 |
-13,3
x | K/w-verhouding 2024 |
-8,55
x | Werknemers | 35 |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 |
-
| Vrij verhandelbaar | 29,94% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ahmad Mortazavi
CEO | Chief Executive Officer | 53 | 01-02-20 |
Director of Finance/CFO | - | - | |
Alan Whitmore
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Trevor Jones
BRD | Director/Board Member | 82 | 28-10-15 |
Director/Board Member | 68 | 11-02-20 | |
Ahmad Mortazavi
CEO | Chief Executive Officer | 53 | 01-02-20 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+23,13% | 52,73 mld. | |
+37,49% | 39 mld. | |
-8,73% | 38,52 mld. | |
+28,09% | 30,38 mld. | |
-12,26% | 26,39 mld. | |
+10,57% | 26,08 mld. | |
+45,05% | 14,15 mld. | |
+32,23% | 12,6 mld. | |
-6,56% | 11,51 mld. |